Neoadjuvant Treatment of Gastric Cancer

2017 ◽  
pp. 149-157
Author(s):  
Yvette H. M. Claassen ◽  
Henk H. Hartgrink ◽  
Wobbe O. De Steur ◽  
Marije Slingerland ◽  
Cornelis J. H. Van de Velde
Keyword(s):  
Gastric Cancer ◽  
Neoadjuvant Treatment

Does Neoadjuvant Treatment for Gastric Cancer Patients with Positive Peritoneal Cytology at Staging Laparoscopy Improve Survival?

2008 ◽  
Vol 15 (10) ◽  
pp. 2684-2691 ◽  
Author(s):  
Brian Badgwell ◽  
Janice N. Cormier ◽  
Sunil Krishnan ◽  
James Yao ◽  
Gregg A. Staerkel ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Neoadjuvant Treatment ◽  
Staging Laparoscopy ◽  
Peritoneal Cytology ◽  
Positive Peritoneal Cytology ◽  
Gastric Cancer Patients

Intensity-modulated radiotherapy for neoadjuvant treatment of gastric cancer

2006 ◽  
Vol 31 (4) ◽  
pp. 292-297 ◽  
Author(s):  
Brian Knab ◽  
Carla Rash ◽  
Karl Farrey ◽  
Ashesh B. Jani
Keyword(s):  
Gastric Cancer ◽  
Neoadjuvant Treatment ◽  
Intensity Modulated Radiotherapy ◽  
Intensity Modulated

Neoadjuvant treatment of gastric cancer with peritoneal dissemination

2006 ◽  
Vol 32 (6) ◽  
pp. 661-665 ◽  
Author(s):  
Y. Yonemura ◽  
E. Bandou ◽  
T. Sawa ◽  
Y. Yoshimitsu ◽  
Y. Endou ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Peritoneal Dissemination ◽  
Neoadjuvant Treatment

Baseline blood neutrophil-lymphocyte ratio to predict treatment response in gastric cancer.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 52-52
Author(s):  
M Diaz Romero
Keyword(s):  
Gastric Cancer ◽  
Stable Disease ◽  
Neoadjuvant Treatment ◽  
Predictive Marker ◽  
Patient Characteristics ◽  
Median Number ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Number Of Patients ◽  
Complete Blood Counts

52 Background: Several studies have shown that the neutrophil to lymphocyte ratio (NLR) in peripheral blood is a prognostic factor of various cancers. Some biomarkers have been associated with response and prognosis in gastric cancer (GC)identify depends specimens on biopsies and limits their use in clinical practice.Pheripheral blood tests at the time of diagnosis can reflect evolution within the tumor. We evaluated whether the NLR would predict response in patients with GC with treatment neoadyuvant or palliative. Methods: We retrospectively analyzed 190 patients with GC (2011-2013) in National Cancer Institute Mexico. 73 patients were treated with chemotherapy neoadjuvant, 30 with chemoradiotherapy neoadjuvant and 117 patients palliative chemotherapy. NLR were calculated from complete blood counts in laboratory test at diagnosis, cutt of values for the NLR were > 2.5 and < 2.5 using median values reported in previous studies. Results: Characteristics of Patients: male 107, female 83, mean age 54 (20-81).The median number of cycles of chemotherapy before of assess response by tomography was 4. The response rate was partial 20.5%, stable disease 36.3% and progression 43.2%.The median NLR :2.9 (1.1-15.2).84 patients were detected with NLR < 2.5 and 106 patients with NLR greater 2.5. Low NLR group patients had a better disease control (partial response and stable disease) in 68 % vs. 47.1% than high NLR( p = 0.028). Progression of disease was reported in 32 %( n=27) with low NLR and 52.9 %( n=56) of group high NLR (P=0.002). Patients with neoadjuvant treatment 50 underwent surgery 30 with NLR ratio lesser 2.5 and 20 high.There are more advanced disease in patients greater 2.5 NLR than < 2.5 80 vs 56 (p=0.036). Response pathological complete after surgery in 2 patients with a lower value and 1 patient with 2.5. Overall survival in low NLR is longer than in group patients NLR >2.5, 11.3 vs. 9.1 months (p=0.49). Conclusions: These data give evidence that baseline NLR could be predictive marker of response and prognosis in patients with GC undergoing treatment. Limitations to our analysis are a small number of patients, short follow-up and will need to be stratified according to patient characteristics and treatment.

scholarly journals Impact of interval timing to surgery on tumor response after neoadjuvant treatment for gastric cancer

2020 ◽  
Vol 112 ◽  
Author(s):  
Juan Ocaña Jiménez ◽  
Pablo Priego ◽  
Marta Cuadrado ◽  
Luis Alberto Blázquez ◽  
Silvia Sánchez Picot ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tumor Response ◽  
Neoadjuvant Treatment ◽  
Interval Timing

scholarly journals Gastric Lavage Malignant Cells (yGL) and Hypohemoglobinemia (yAnemia) as New Systems of Tumor Regression Grading and Prognostic Prediction for Gastric Cancer After Neoadjuvant Treatment

2019 ◽  
Vol 39 (2) ◽  
pp. 1019-1027 ◽  
Author(s):  
EDOARDO VIRGILIO ◽  
ENRICO GIARNIERI ◽  
MARIA ROSARIA GIOVAGNOLI ◽  
MONICA MONTAGNINI ◽  
ANTONELLA PROIETTI ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tumor Regression ◽  
Neoadjuvant Treatment ◽  
Gastric Lavage ◽  
Malignant Cells ◽  
Regression Grading ◽  
Prognostic Prediction

ECX as neoadjvuant chemotherapy for gastric cancer in South America.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15190-e15190
Author(s):  
Leandro Machado Colli ◽  
Antonio Carlos Godoy ◽  
Bruno Filardi ◽  
Jose Marcio Barros Figueiredo ◽  
José Sebastião Santos ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Disease Progression ◽  
Locally Advanced ◽  
Pathologic Complete Response ◽  
Neoadjuvant Treatment ◽  
Progression Free Survival ◽  
Complete Response ◽  
Brazilian Population ◽  
South American ◽  
South American Population

e15190 Background: Gastric cancer is a common malignant disease with a high mortality rate. Neoadjuvant treatment is efficient, but not the first option for treatment in all countries. Studies of neadjuvant chemotherapy in gastric cancer in South American countries are lacking. The aim of this retrospective analysis was to investigate the use of the ECX (epirubicin, cisplatin, and capecitabine) regimen in the neoadjuvant therapy in a Brazilian population. Methods: 25 patients (median age, 61; range 36-78 years; 14 pts >60 years) with locally advanced gastric adenocarcinoma received three courses of preoperative chemotherapy with epirubicin 50 mg/m², day 1, cisplatin 60 mg/m², day 1, and capecitabine 625 mg/m² bid, days 2-21, of a 21-day cycle. Toxicity was assessed by the Common Toxicity Criteria (CTC) after every cycle. Progression-free survival (PFS) was defined as time from diagnosis to disease progression assessed by CT. Results: 21 pts completed all three planned cycles of neoadjuvant chemotherapy. Four patients receiced surgery earlier than planned due to bleeding (1), toxicity (1), abdominal infection (1), and non-adherence to treatment (1). Three patients could not be operated due to disease progression. 70% of operated patients had curative resection with two pathologic complete response. Only six out 25 patients had disease progression and only two died after a median follow-up of 11.5 months (range 3.4-20.2). Median PFS and overall survival were not reached. Toxicities grade 3-4 were neutropenia (28%), febrile neutropenia (8%), bleeding (8%), and heart failure (6,2%). Conclusions: ECX is a efficacious neoadjuvant treatment in the Brazilian population and also well tolerated and safe. However, more studies with a larger South American population are needed.

Immunohistochemical expression of receptor-tyrosine-kinase in patients with gastric cancer: A multicenter study in Japan.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 41-41
Author(s):  
Yutaka Kimura ◽  
Yukinori Kurokawa ◽  
Nariaki Matsuura ◽  
Junya Fujita ◽  
Hiroshi Imamura ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tyrosine Kinase ◽  
Receptor Tyrosine Kinase ◽  
Neoadjuvant Treatment ◽  
Rank Test ◽  
Test Results ◽  
Her2 Positive ◽  
Exact Test ◽  
Log Rank Test

41 Background: Treatment of HER2 positive gastric cancer (GC) with trastuzumab, receptor-tyrosine-kinase (RTK) inhibitor, has led to significant gains in overall survival. Several other targeted therapies are currently undergoing preclinical and clinical testing in some malignancies and GC, directed against diverse oncogenic RTK, therefor it is important to define the expression pattern of target RTK in GC. A multicenter retrospective study was conducted to evaluate the correlation between the expression of some RTKs, HER2, EGFR and c-KIT, and clinicopathological features in GC. Methods: A total of 153 cases with GC which was surgically resected between 2000 and 2006 were registered from nine hospitals. The neoadjuvant treatment cases were excluded. Tumors were centrally examined for HER2, EGFR and c-KIT status with immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) for HER2. The relation between the expressions of HER2, EGFR and c-KIT and clinicopathological factors was examined by Fisher’s exact test. The hazard ratio (HR) for death was estimated, and overall survivals (OS) were compared between positive and negative cases of HER2, EGFR, and c-KIT using log-rank test. Results: The proportion of positive cases with IHC of HER2, EGFR and c-KIT was 7.8%, 14.4% and 11.1%, respectively. There was no significant correlation between the expression of HER2, EGFR and c-KIT and differentiation, location and depth. HER2-positive cases tended to be more frequent in differentiated type tumors. EGFR-positve cases were more frequent in lymph node metastasis (P=0.013). c-KIT-positive cases tended to be more frequent in T1-T2 tumors. OS in HER2-positive cases were clearly worse than in HER2-negative cases (HR 2.23 (95%CI, 1.16-4.38); P=0.014). EGFR-positive cases had a tendency to be worse than in EGFR-negative cases (HR 1.60 (95%CI, 0.94-2.71); P=0.082). c-KIT-negative cases were worse than in c-KIT-positive cases (HR 0.42 (95%CI, 0.17-1.02); P=0.048). Conclusions: This study showed that HER2 expression is a factor of poor prognosis and that EGFR-positive status and c-KIT-negative status tended to be associated with worse outcomes in resected GC.

Sign in / Sign up

Export Citation Format

Share Document